Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
Department of Medical Oncology, Saint-André Hospital, University Hospital, CHU, Bordeaux, France; Bordeaux University, Bordeaux, France. Electronic address: amaury.daste@chu-bordeaux.fr.
Amaury
A
Daste
Department of Otolaryngology - Head and Neck Surgery, Pellegrin Hospital, University Hospital, CHU, Bordeaux, France.
Erwan
E
de Mones
Department of Medical Oncology, Saint-André Hospital, University Hospital, CHU, Bordeaux, France.
Laurence
L
Digue
Department of Medical Oncology, Saint-André Hospital, University Hospital, CHU, Bordeaux, France; Bordeaux University, Bordeaux, France.
Louis
L
François
Department of Medical Oncology, Saint-André Hospital, University Hospital, CHU, Bordeaux, France.
Charlotte
C
Domblides
Department of Radiation Therapy, Haut Leveque Hospital, University Hospital, CHU, Bordeaux, France.
Charles
C
Dupin
Neuroradiology Department, Pellegrin Hospital, University Hospital, CHU, Bordeaux, France.
Antoine
A
Bigourdan
Department of Medical Oncology, Saint-André Hospital, University Hospital, CHU, Bordeaux, France; Bordeaux University, Bordeaux, France.
Alain
A
Ravaud
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D018450:Disease Progression; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab; D000077195:Squamous Cell Carcinoma of Head and Neck
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab
Head and neck cancer; Oral cancer